On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
FridayJan 27, 2017 1:54 pm

NetworkNewsBreaks – Inventergy Global, Inc. (NASDAQ: INVT) Focuses on Unparalleled IP Expertise

Intellectual property (IP) has grown from a market mainly accredited to the tech industry to an invaluable component in the legal and business worlds. Corporations are dedicating more resources to ensure their IP assets are managed appropriately in order to meet the growing needs of shareholders. Inventergy Global, Inc. (NASDAQ: INVT) doesn’t just offer corporations greater value from their inventions and ideas, but a partnership led by some of the most experienced professionals in the industry. Founded by Joe Beyers, the previous leader of global licensing for Hewlett-Packard (NYSE: HPE), the company’s team boasts more than 100 years of combined…

Continue Reading

FridayJan 27, 2017 1:49 pm

NetworkNewsBreaks – Lightbridge (NASDAQ: LTBR) Welcomes Renewal of U.S.-Norway 123 Agreement on Commercial Nuclear Energy

The U.S. government recently approved the renewal of a commercial nuclear energy agreement with Norway, a move welcomed by nuclear fuel technology company Lightbridge Corporation (NASDAQ: LTBR). The 123 Agreement legislation was signed in December 2016, following overwhelmingly positive votes by Congress. The legislation also paves the way for Lightbridge to continue research and testing of its metallic nuclear fuel at Norway’s 20 MW Halden research reactor. The innovative, next-generation fuel, made with U.S.-enriched uranium, promises improved safety and economics for nuclear plants, a fact also recognized by the Norwegian Radiation Protection Authority in January this year. On a broader…

Continue Reading

FridayJan 27, 2017 1:46 pm

NetworkNewsBreaks – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) Tackles Lactose Intolerance, Metabolic Syndrome with RP-G28

Ritter Pharmaceuticals (NASDAQ: RTTR) is a specialty pharmaceutical company developing therapeutics that modulate the gut microbiome to treat gastrointestinal diseases. The company’s first novel microbiome modulator, RP-G28, is currently in a phase 2b/3 study in humans for the treatment of lactose intolerance. More than one billion people suffer from lactose intolerance globally, and the company believes RP-G28 has the potential to become the first FDA-approved drug for the treatment of the disease. In previous human studies, RP-G28 has demonstrated significant beneficial changes to the gut microbiome that have been associated with supporting metabolic health. Recently, the company announced a collaborative…

Continue Reading

FridayJan 27, 2017 12:55 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on January 27, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: VEND 50.15% – News: Issues letter to shareholders PULM 34.01% – News: RDI issues research report ESSI 8.31% – News: Moving on momentum of growth capital financing, operational updates RYES 6.73% – News: Acquires major past producing gold mine AUPH 6.56% – News: Selects Worldwide Clinical Trials as CRO for phase 3 lupus nephritis trial PURE 3.37% – News: Publishes Norovirus Technical Bulletin in response to recent norovirus media coverage IMMU 1.97% – News:…

Continue Reading

FridayJan 27, 2017 12:15 pm

NetworkNewsBreaks – Novan, Inc. (NASDAQ: NOVN) Shares Plunge on Inconsistent Topline Results from SB204 Phase 3 Pivotal Trials

Novan (NASDAQ: NOVN) shares dropped 75% this morning following the release of top-line results from the two, replicate phase 3 pivotal clinical trials for the company’s topical nitric oxide-releasing product candidate SB204 in the treatment of acne vulgaris. In the intent-to-treat analysis, SB204 demonstrated statistical significance on all three co-primary endpoints in NI-AC302, but it demonstrated statistical significance on only one of three co-primary endpoints in NI-AC301. The three co-primary endpoints included the absolute changes in inflammatory and non-inflammatory lesion counts and proportion of patients achieving success, “clear” or “almost clear,” on the Investigator Global Assessment (IGA) at week 12. …

Continue Reading

ThursdayJan 26, 2017 1:36 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on January 26, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: SGLB 37.61% – News: Signs commercial agreement with Pratt & Whitney PLFX 15.38% – News: Enters joint venture with Augmented Reality Technology Specialist Augmently, Inc. QPAG 12.50% – News: Expands its self-service payment solutions ANY 7.55% – News: Launches second advertising and lead generation campaign for Glassware 2.0™ INVT 6.67% – News: Reaches agreement with preferred stockholders to extend redemption timeframe KNDI 6.03% – News: JV’s EV Model K11 receives MIIT recommendation MTNB 5.47%…

Continue Reading

ThursdayJan 26, 2017 1:36 pm

NetworkNewsBreaks – Gopher Protocol, Inc. (GOPH) Competes in $1B GPS Personal Tracking Industry with Innovative GuardianPatch

Gopher Protocol (OTCQB: GOPH) develops real-time, self-learning (heuristic) mobile technologies. In collaboration with partner Guardian Patch LLC, Gopher has developed Guardian Patch Location Technology. The company’s patented Integrated Circuit (IC) GopherInsight technology is part of the muscle behind the mobile app designed to track valuables such as electronics or other objects, loved ones or even pets. In November 2016, the GuardianPatch patent was finalized and filed. The product is expected to hit the market in 2017, aligned with the current boom in GPS personal tracking devices and applications, a market expected to break $1 billion in 2017. To learn more,…

Continue Reading

ThursdayJan 26, 2017 1:34 pm

NetworkNewsBreaks – Kindred Biosciences, Inc.’s (NASDAQ: KIN) Strategy to Capture its Share of $7.5B Animal Health Market

Kindred Biosciences (NASDAQ: KIN) is a development-stage biopharmaceutical company taking aim at the $7.5 billion animal health market, specifically focusing on therapies for pets. The company has established a simple, yet effective, strategy to capture its share of the market: leverage investments made in human pharmaceutical R&D to develop therapies that offer the benefits of lower risk, lower cost, and shorter time-to-market. Kindred currently has in development an exciting pipeline of more than 20 programs of high-value products for dogs, cats and horses. The company’s lead candidates are Mirataz™, a weight loss product for cats, and Zimeta™ to treat fever…

Continue Reading

ThursdayJan 26, 2017 1:31 pm

NetworkNewsBreaks – Apricus Biosciences, Inc. (NASDAQ: APRI) Continues to Advance Erectile Dysfunction Treatment on Global Scale

Apricus Biosciences (NASDAQ: APRI) is focused on advancing the development and commercialization of its innovative, life-improving treatment products in urology and rheumatology. The company’s pipeline includes Vitaros®, a locally applied topical cream for the treatment of erectile dysfunction, a condition affecting roughly 150 million men worldwide. Containing alprostadil in combination with the company’s novel excipient, Vitaros delivers a rapid onset with significant efficacy and an encouraging safety profile. In a study of more than 3,000 patients, Vitaros demonstrated positive, clinically meaningful responses in measures of erectile function. The FDA recently determined that Vitaros, under current regulations, is now considered a…

Continue Reading

ThursdayJan 26, 2017 1:26 pm

NetworkNewsBreaks – Regulatory Approvals Mark Significant Milestones for Trendlines Group Ltd.’s (TRNLY) Gordian Surgical

Gordian Surgical, a medical portfolio company of Trendlines Group Ltd. (OTCQX: TRNLY), is making significant advances in the way surgical procedures are performed with its TroClose1200™, which in the fourth quarter of 2016 was awarded both U.S. FDA regulatory clearance and CE Mark certification. TroClose1200 was designed to provide surgeons "two-in-one" functionality. The device acts as a trocar, through which surgical instruments enter the abdomen; and as a device to close internal incisions made during surgery. It works by enabling the insertion of sutures into the tissue at the beginning of the procedure and is anchored to remain in place…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217